Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib, Open-label Study of Alpelisib (BYL719) in Combination With Cisplatin in Patients With HPV+ Solid Tumor Malignancies

NCT02620839 is registered in ClinicalTrials.gov with Pamela Munster as lead sponsor.

NCT NCT02620839
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02620839 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib, Open-label Study of Alpelisib (BYL719) in Combination With Cisplatin in Patients With HPV+ Solid Tumor Malignancies
Lead sponsor
Pamela Munster
Phase
Phase 1
Overall status
Terminated
Start date
December 1, 2016
Completion date
January 28, 2019
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors